Informatics-guided drug repurposing for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
作者信息
Kiseleva Anna A, Golemis Erica A
机构信息
Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, United States; Kazan Federal University, 420000 Kazan, Russian Federation.
Molecular Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, United States.
出版信息
EBioMedicine. 2020 Feb;52:102628. doi: 10.1016/j.ebiom.2020.102628. Epub 2020 Jan 22.
Abstract
摘要
相似文献
1
Informatics-guided drug repurposing for Autosomal Dominant Polycystic Kidney Disease (ADPKD).信息学引导的常染色体显性多囊肾病（ADPKD）药物再利用
EBioMedicine. 2020 Feb;52:102628. doi: 10.1016/j.ebiom.2020.102628. Epub 2020 Jan 22.
2
Drug repurposing in autosomal dominant polycystic kidney disease.药物再利用治疗常染色体显性遗传多囊肾病。
Kidney Int. 2023 May;103(5):859-871. doi: 10.1016/j.kint.2023.02.010. Epub 2023 Mar 2.
3
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.优先考虑多囊肾病药物靶点和从小囊性和囊性 Pkd2 模型基因表达逆转的小鼠中重新利用候选药物。
Mol Med. 2023 May 22;29(1):67. doi: 10.1186/s10020-023-00664-z.
4
RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.RAPID-ADPKD（亚太地区常染色体显性遗传性多囊肾病快速进展患者的回顾性流行病学研究）：一项多中心、回顾性队列研究的研究方案。
BMJ Open. 2020 Feb 6;10(2):e034103. doi: 10.1136/bmjopen-2019-034103.
5
A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells.一种用于多囊肾病（PKD）药物再利用的高通量筛选平台，利用了鼠类和人类 ADPKD 细胞。
Sci Rep. 2020 Mar 6;10(1):4203. doi: 10.1038/s41598-020-61082-3.
6
Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.常染色体显性多囊肾病（ADPKD）进展的临床和实验室标志物：综述
Minerva Med. 2015 Feb;106(1):53-64. Epub 2014 Oct 10.
7
Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.常染色体显性遗传多囊肾病和常染色体隐性遗传多囊肾病进展的预测因素。
Pediatr Nephrol. 2021 Sep;36(9):2639-2658. doi: 10.1007/s00467-020-04869-w. Epub 2021 Jan 21.
8
Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).解决常染色体显性遗传性多囊肾病临床试验终点的需求：多囊肾病结局联盟（PKDOC）的报告。
Am J Kidney Dis. 2019 Apr;73(4):533-541. doi: 10.1053/j.ajkd.2018.11.001. Epub 2018 Dec 29.
9
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).常染色体显性遗传多囊肾病治疗领域数据标准：多囊肾病结局联盟（PKDOC）报告。
Am J Kidney Dis. 2015 Oct;66(4):583-90. doi: 10.1053/j.ajkd.2015.04.044. Epub 2015 Jun 15.
10
Hypomagnesaemia is absent in children with autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病患儿中无低镁血症。
Ann Clin Biochem. 2019 Jan;56(1):90-94. doi: 10.1177/0004563218785190. Epub 2018 Jul 2.
引用本文的文献
1
A Patient-Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates.一种源自患者的多囊肾病三维囊肿模型，可模拟疾病发展并对重新利用的候选药物作出反应。
Clin Transl Sci. 2025 Apr;18(4):e70214. doi: 10.1111/cts.70214.
本文引用的文献
1
Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles.从疾病阶段特异性基因表达谱中优先选择新型 ADPKD 药物候选物。
EBioMedicine. 2020 Jan;51:102585. doi: 10.1016/j.ebiom.2019.11.046. Epub 2019 Dec 24.
2
Autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病。
Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25.
3
Drug repurposing in kidney disease.肾脏疾病的药物再利用。
Kidney Int. 2018 Jul;94(1):40-48. doi: 10.1016/j.kint.2017.12.026. Epub 2018 Apr 6.
4
Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).甘替斯培抑制常染色体显性多囊肾病（ADPKD）中的纤毛和囊泡生成。
FASEB J. 2018 May;32(5):2735-2746. doi: 10.1096/fj.201700909R. Epub 2018 Jan 10.
5
Profiling conserved biological pathways in Autosomal Dominant Polycystic Kidney Disorder (ADPKD) to elucidate key transcriptomic alterations regulating cystogenesis: A cross-species meta-analysis approach.分析常染色体显性多囊肾病（ADPKD）中保守的生物学通路以阐明调节囊肿形成的关键转录组改变：一种跨物种荟萃分析方法。
Gene. 2017 Sep 5;627:434-450. doi: 10.1016/j.gene.2017.06.059. Epub 2017 Jul 1.
6
Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.结直肠癌细胞系蛋白质组可代表原发性肿瘤并预测药物敏感性。
Gastroenterology. 2017 Oct;153(4):1082-1095. doi: 10.1053/j.gastro.2017.06.008. Epub 2017 Jun 16.
7
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.癌症的特征：与多囊肾病发病机制的相关性。
Nat Rev Nephrol. 2015 Sep;11(9):515-34. doi: 10.1038/nrneph.2015.46. Epub 2015 Apr 14.
8
Src inhibition ameliorates polycystic kidney disease.Src抑制可改善多囊肾病。
J Am Soc Nephrol. 2008 Jul;19(7):1331-41. doi: 10.1681/ASN.2007060665. Epub 2008 Apr 2.
9
The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.mTOR信号通路受多囊蛋白-1调控，抑制该通路可逆转多囊肾病中的肾囊肿形成。
Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71. doi: 10.1073/pnas.0509694103. Epub 2006 Mar 27.
10
New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies.运用SAGE技术与微阵列技术相结合对常染色体显性多囊肾病分子途径的新见解
Genomics. 2004 Sep;84(3):497-510. doi: 10.1016/j.ygeno.2004.03.009.
Zotero 插件